Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27121939,bioavailability,"Following single belimumab SC doses, bioavailability was 74-82%, indicating that belimumab SC was well absorbed, and bioavailability was similar among the three SC groups.","Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121939/),%,74-82,1937,DB08879,Belimumab
,24117862,bioavailability,The bioavailability of the single subcutaneous dose of 200 mg belimumab in the subjects was estimated to be 77·5%.,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),%,77·5,28951,DB08879,Belimumab
,24117862,Time to the maximum serum concentration,Time to the maximum serum concentration after subcutaneous injection was 6·5 days (median).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,6·5,28952,DB08879,Belimumab
,24117862,terminal half-life,The geometric mean terminal half-life was comparable between the two administration routes (17·7 days intravenous and 15·9 days subcutaneous).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,17·7,28953,DB08879,Belimumab
,24117862,terminal half-life,The geometric mean terminal half-life was comparable between the two administration routes (17·7 days intravenous and 15·9 days subcutaneous).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,15·9,28954,DB08879,Belimumab
,23681782,terminal half-life,"The estimated population terminal half-life was 19.4 days and steady-state volume of distribution (Vss) was 5.29 L for the currently approved 10 mg/kg dose used in the Phase 3 trials, with an estimated CL of 215 mL/day.",Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681782/),d,19.4,47665,DB08879,Belimumab
,23681782,steady-state volume of distribution (Vss),"The estimated population terminal half-life was 19.4 days and steady-state volume of distribution (Vss) was 5.29 L for the currently approved 10 mg/kg dose used in the Phase 3 trials, with an estimated CL of 215 mL/day.",Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681782/),l,5.29,47666,DB08879,Belimumab
,23681782,CL,"The estimated population terminal half-life was 19.4 days and steady-state volume of distribution (Vss) was 5.29 L for the currently approved 10 mg/kg dose used in the Phase 3 trials, with an estimated CL of 215 mL/day.",Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681782/),[ml] / [d],215,47667,DB08879,Belimumab
,18786258,terminal elimination half-life,"Long terminal elimination half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69 to 112 ml/kg) were consistent with a fully human antibody.","Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786258/),d,8.5 to 14.1,48287,DB08879,Belimumab
,18786258,clearance,"Long terminal elimination half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69 to 112 ml/kg) were consistent with a fully human antibody.","Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786258/),[ml] / [d·kg],7,48288,DB08879,Belimumab
,18786258,volume of distribution,"Long terminal elimination half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69 to 112 ml/kg) were consistent with a fully human antibody.","Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786258/),[ml] / [kg],69 to 112,48289,DB08879,Belimumab
,27072354,clearance,"The estimates for clearance, steady-state volume of distribution, and bioavailability were 208 mL/day, 5250 mL, and 76%, respectively.",Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27072354/),[ml] / [d],208,117897,DB08879,Belimumab
,27072354,steady-state volume of distribution,"The estimates for clearance, steady-state volume of distribution, and bioavailability were 208 mL/day, 5250 mL, and 76%, respectively.",Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27072354/),ml,5250,117898,DB08879,Belimumab
,27072354,bioavailability,"The estimates for clearance, steady-state volume of distribution, and bioavailability were 208 mL/day, 5250 mL, and 76%, respectively.",Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27072354/),%,76,117899,DB08879,Belimumab
,27668697,trough concentration,Week 8 median trough concentration was 113 µg/mL.,Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus . ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668697/),[μg] / [ml],113,151039,DB08879,Belimumab
,32699034,trough concentration,"Week-52, geometric mean (95% CI) belimumab trough concentration was 56.2 (45.2 to 69.8) µg/mL.","Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32699034/),[μg] / [ml],56.2,151299,DB08879,Belimumab
,27536436,terminal elimination half-life,"The PK profile of single-dose belimumab was approximately dose proportional, and the long terminal elimination half-life (12.4-15.7 days), low clearance (3.55-4.65 mL/day/kg), and small volume of distribution (76.2-80.1 mL/kg) were consistent with a fully humanized antibody.","Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536436/),d,12.4-15.7,188920,DB08879,Belimumab
,27536436,clearance,"The PK profile of single-dose belimumab was approximately dose proportional, and the long terminal elimination half-life (12.4-15.7 days), low clearance (3.55-4.65 mL/day/kg), and small volume of distribution (76.2-80.1 mL/kg) were consistent with a fully humanized antibody.","Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536436/),[ml] / [d·kg],3.55-4.65,188921,DB08879,Belimumab
,27536436,volume of distribution,"The PK profile of single-dose belimumab was approximately dose proportional, and the long terminal elimination half-life (12.4-15.7 days), low clearance (3.55-4.65 mL/day/kg), and small volume of distribution (76.2-80.1 mL/kg) were consistent with a fully humanized antibody.","Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536436/),[ml] / [kg],76.2-80.1,188922,DB08879,Belimumab
,31953740,Cmax,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[μg] / [ml],221,200169,DB08879,Belimumab
,31953740,area under the concentration-time curve (time 0 to last quantifiable concentration),"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[d·μg] / [ml],2395,200170,DB08879,Belimumab
,31953740,area under the concentration-time curve (time 0 to last quantifiable concentration),"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),d,14.6,200171,DB08879,Belimumab
,31953740,area under the concentration-time curve (time 0 to last quantifiable concentration),"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[ml] / [d·kg],4.06,200172,DB08879,Belimumab
,31953740,terminal half-life,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[d·μg] / [ml],2395,200173,DB08879,Belimumab
,31953740,terminal half-life,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[ml] / [d·kg],4.06,200174,DB08879,Belimumab
,31953740,systemic clearance,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[d·μg] / [ml],2395,200175,DB08879,Belimumab
,31953740,systemic clearance,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[ml] / [d·kg],4.06,200176,DB08879,Belimumab
,31953740,volume of distribution,"Geometric mean Cmax, area under the concentration-time curve (time 0 to last quantifiable concentration), terminal half-life, systemic clearance, and volume of distribution were 221 μg/mL, 2395 day·μg/mL, 14.6 days, 4.06 mL/day/kg, and 85.7 mL/kg, respectively.","Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31953740/),[ml] / [kg],85.7,200177,DB08879,Belimumab
,33245847,clearance,"The popPK model estimated clearance of 158 mL/day, steady-state volume of distribution of 3.5 L, terminal half-life of 16.3 days, and distribution half-life of 0.8 days in the overall population.",Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245847/),[ml] / [d],158,221403,DB08879,Belimumab
,33245847,steady-state volume of distribution,"The popPK model estimated clearance of 158 mL/day, steady-state volume of distribution of 3.5 L, terminal half-life of 16.3 days, and distribution half-life of 0.8 days in the overall population.",Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245847/),l,3.5,221404,DB08879,Belimumab
,33245847,terminal half-life,"The popPK model estimated clearance of 158 mL/day, steady-state volume of distribution of 3.5 L, terminal half-life of 16.3 days, and distribution half-life of 0.8 days in the overall population.",Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245847/),d,16.3,221405,DB08879,Belimumab
,33245847,distribution half-life,"The popPK model estimated clearance of 158 mL/day, steady-state volume of distribution of 3.5 L, terminal half-life of 16.3 days, and distribution half-life of 0.8 days in the overall population.",Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33245847/),d,0.8,221406,DB08879,Belimumab
,27163500,Maximum observed serum concentration,"Maximum observed serum concentration was slightly higher with the autoinjector (27.0 vs 25.3 µg/mL) and area under the concentration-time curve slightly lower (701 vs 735 day · μg/mL), compared with the prefilled syringe.",Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163500/),[μg] / [ml],27.0,246486,DB08879,Belimumab
,27163500,Maximum observed serum concentration,"Maximum observed serum concentration was slightly higher with the autoinjector (27.0 vs 25.3 µg/mL) and area under the concentration-time curve slightly lower (701 vs 735 day · μg/mL), compared with the prefilled syringe.",Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163500/),[μg] / [ml],25.3,246487,DB08879,Belimumab
,27163500,area under the concentration-time curve,"Maximum observed serum concentration was slightly higher with the autoinjector (27.0 vs 25.3 µg/mL) and area under the concentration-time curve slightly lower (701 vs 735 day · μg/mL), compared with the prefilled syringe.",Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163500/),[d·μg] / [ml],701,246488,DB08879,Belimumab
,27163500,area under the concentration-time curve,"Maximum observed serum concentration was slightly higher with the autoinjector (27.0 vs 25.3 µg/mL) and area under the concentration-time curve slightly lower (701 vs 735 day · μg/mL), compared with the prefilled syringe.",Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163500/),[d·μg] / [ml],735,246489,DB08879,Belimumab
,27163500,injection-site pain scores,Median injection-site pain scores were low (0 after 1 hour).,Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163500/),,0,246490,DB08879,Belimumab
